These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 30209390)

  • 1. In vivo CRISPR editing with no detectable genome-wide off-target mutations.
    Akcakaya P; Bobbin ML; Guo JA; Malagon-Lopez J; Clement K; Garcia SP; Fellows MD; Porritt MJ; Firth MA; Carreras A; Baccega T; Seeliger F; Bjursell M; Tsai SQ; Nguyen NT; Nitsch R; Mayr LM; Pinello L; Bohlooly-Y M; Aryee MJ; Maresca M; Joung JK
    Nature; 2018 Sep; 561(7723):416-419. PubMed ID: 30209390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
    Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovering the Genome-Wide Activity of CRISPR-Cas Nucleases.
    Tsai SQ
    ACS Chem Biol; 2018 Feb; 13(2):305-308. PubMed ID: 29281250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
    Kleinstiver BP; Pattanayak V; Prew MS; Tsai SQ; Nguyen NT; Zheng Z; Joung JK
    Nature; 2016 Jan; 529(7587):490-5. PubMed ID: 26735016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
    Chadwick AC; Wang X; Musunuru K
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish.
    Hruscha A; Krawitz P; Rechenberg A; Heinrich V; Hecht J; Haass C; Schmid B
    Development; 2013 Dec; 140(24):4982-7. PubMed ID: 24257628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome editing with the donor plasmid equipped with synthetic crRNA-target sequence.
    Ishibashi R; Abe K; Ido N; Kitano S; Miyachi H; Toyoshima F
    Sci Rep; 2020 Aug; 10(1):14120. PubMed ID: 32839482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases.
    Zischewski J; Fischer R; Bortesi L
    Biotechnol Adv; 2017; 35(1):95-104. PubMed ID: 28011075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms.
    Javed MR; Sadaf M; Ahmed T; Jamil A; Nawaz M; Abbas H; Ijaz A
    Curr Microbiol; 2018 Dec; 75(12):1675-1683. PubMed ID: 30078067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving Plant CRISPR Targeting that Limits Off-Target Effects.
    Wolt JD; Wang K; Sashital D; Lawrence-Dill CJ
    Plant Genome; 2016 Nov; 9(3):. PubMed ID: 27902801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indiscriminate ssDNA cleavage activity of CRISPR-Cas12a induces no detectable off-target effects in mouse embryos.
    Wei Y; Zhou Y; Liu Y; Ying W; Lv R; Zhao Q; Zhou H; Zuo E; Sun Y; Yang H; Zhou C
    Protein Cell; 2021 Sep; 12(9):741-745. PubMed ID: 33797032
    [No Abstract]   [Full Text] [Related]  

  • 13. [Methods of Evaluating the Efficiency of CRISPR/Cas Genome Editing].
    Lomov NA; Viushkov VS; Petrenko AP; Syrkina MS; Rubtsov MA
    Mol Biol (Mosk); 2019; 53(6):982-997. PubMed ID: 31876277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Web-Based CRISPR Toolkits: Cas-OFFinder, Cas-Designer, and Cas-Analyzer.
    Hwang GH; Kim JS; Bae S
    Methods Mol Biol; 2021; 2162():23-33. PubMed ID: 32926375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
    Chadwick AC; Musunuru K
    Curr Atheroscler Rep; 2017 Jul; 19(7):32. PubMed ID: 28550381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
    Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
    Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A beginner's guide to gene editing.
    Harrison PT; Hart S
    Exp Physiol; 2018 Apr; 103(4):439-448. PubMed ID: 29282799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off- and on-target effects of genome editing in mouse embryos.
    Ayabe S; Nakashima K; Yoshiki A
    J Reprod Dev; 2019 Feb; 65(1):1-5. PubMed ID: 30518723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current advances in overcoming obstacles of CRISPR/Cas9 off-target genome editing.
    Aquino-Jarquin G
    Mol Genet Metab; 2021; 134(1-2):77-86. PubMed ID: 34391646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.